Archive - GLP-1 Observer

Foundayo Coverage and Dual-Agonist Liver Updates

Week Of May 23 - May 29, 2026

May 29 • Michael Parker, MD

Retatrutide’s Results, Wegovy Gears Up For Europe

Week Of May 16 – May 22, 2026

May 22 • Michael Parker, MD

Maintenance Trials and Drug Responders

Week Of May 9 – May 15, 2026

May 15 • Michael Parker, MD

Combos, CagriSema, and Heart Failure

Week Of May 2 – May 8, 2026

May 8 • Michael Parker, MD

Survodutide’s Number, Foundayo’s Bias

Week Of April 25 – May 1, 2026

May 1 • Michael Parker, MD

April 2026

Sites, Selectivity, and Petrelintide Positioning

Week Of April 18 – April 24, 2026

Apr 24 • Michael Parker, MD

Mortality, Muscle, and a Crowded Tri-Agonist Race

Week Of April 11 – April 17, 2026

Apr 17 • Michael Parker, MD

AstraZeneca, Pharmacokinetics, and a Crowded Pipeline

Week Of April 4 – April 10, 2026

Apr 10 • Michael Parker, MD

The GLP-1 Scoville Scale - April 2026

What’s hottest in the GLP-1 pipeline right now

Apr 10 • Michael Parker, MD

Oral Race, Open Questions

Week Of March 28 – April 3, 2026

Apr 3 • Michael Parker, MD

March 2026

Enzymes and Early Signals

Week Of March 21 – March 27, 2026

Mar 27 • Michael Parker, MD

Approvals, Pills, and Brain Rewards

Week Of March 14 – March 20, 2026

Mar 20 • Michael Parker, MD

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts